BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

...Breast cancer tRNA initiator methionine (tRNA-iMet) Cell culture studies suggest promoting interactions between tRNA-iMet and microRNA-34a (miR-34a)...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...INDICATION: Breast cancer Cell culture studies suggest promoting interactions between miR-34a and tRNA-iMet could help treat...
...help treat breast cancer. In a panel of human breast cancer cell lines, levels of miR-34a...
...miR-34a in a mouse model of breast cancer. TARGET/MARKER/PATHWAY: Argonaute RISC catalytic component 2 (AGO2); MicroRNA-34a (miR-34a)...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Pulmonary

...Bronchopulmonary dysplasia (BPD); acute lung injury Patient sample, mouse and cell culture studies suggest inhibiting miR-34a...
...of miR-34a increased alveolar size compared with normal miR-34a expression, and in the ALI model, miR-34a...
...included testing surfactant as a vehicle for alveolar compartment-targeted delivery of the miR-34a antagomir. TARGET/MARKER/PATHWAY: MicroRNA-34a (miR-34a)...
BioCentury | Sep 21, 2017
Translation in Brief

No vehicle, no problem

...and conjugated to a folate molecule via click chemistry. The authors showed a FolamiR mimicking microRNA-34a (miR-34a)...
...folate-expressing breast cancer and non-small cell lung cancer (NSCLC). In the models, the FolamiR boosted miR-34a...
...Science Translational Medicine (2017) Winnie Pong, Staff Writer, and Karen Tkach Tuzman, Senior Writer patisiran Alnylam Pharmaceuticals Inc. Purdue University Sanofi MicroRNA-34a (miR-34a) Prostate-specific...
BioCentury | Sep 19, 2017
Distillery Techniques

Drug delivery

...of a therapeutic miRNA-34a (miR-34a) mimic increased tumor levels of miR-34a and decreased expression of miR-34a...
...Kasinski, Purdue University, West Lafayette, Ind. email: akasinski@purdue.edu Karen Tkach Tuzman Purdue University B cell lymphoma 2 (BCL-2) (BCL2) MicroRNA-34a (miR-34a) Cancer...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Autoimmune disease

...INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest inhibiting miR-34a could help treat RA...
...help treat RA. In dendritic cells (DCs) in synovial tissue samples from patients, levels of miR-34a...
...miR-34a expression. Next steps could include identifying and testing miR-34a inhibitors in the models. TARGET/MARKER/PATHWAY: MicroRNA-34a (miR-34a)...
BioCentury | May 16, 2017
Financial News

Synlogic finds public route, raises $42M

Synthetic biology company Synlogic Inc. (Cambridge, Mass.) will become a publicly traded entity via a reverse merger with Mirna Therapeutics Inc. (NASDAQ:MIRN). The combined company will keep Synlogic's name and develop that company's programs, including...
BioCentury | Sep 26, 2016
Clinical News

MRX34: Phase I discontinued

Mirna voluntarily terminated an open-label, dose-escalation, dose-expansion, U.S. and Korean Phase I trial of IV MRX34 after a fifth, immune-related serious adverse event was reported in patients who received the compound. The company said the...
BioCentury | Oct 2, 2015
Financial News

Edge, Mirna price IPOs

Edge Therapeutics Inc. (NASDAQ:EDGE) and Mirna Therapeutics Inc. (NASDAQ:MIRN) each began trading Thursday after pricing IPOs. Edge gained $1.94 (18%) to $12.94 after it raised $80.5 million through the sale of 7.3 million shares at...
BioCentury | Aug 26, 2015
Financial News

IPO roundup: Mirna, RainDance

Cancer company Mirna Therapeutics Inc. (Austin, Texas) filed to go public, while genetic research tool play RainDance Technologies Inc. (Billerica, Mass.) pulled its IPO. Mirna proposed to raise up to $80.5 million in an IPO...
Items per page:
1 - 10 of 39